Superworth

Angiodynamics EV/EBIT ANGO

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2013.

Today, Oct 23, 2026
n/m
an operating loss
Last meaningful
33.7×
Apr 2024
10-year median
33.0×
10-year range
16.7× to 492×
Peer median
22.8×

Angiodynamics has no meaningful EV/EBIT today: it made an operating loss of $36.6M over the last twelve months.

It was last meaningful in Apr 2024, at 33.7×.

On the days it had one over the last ten years, its median was 33.0×, from 16.7× in Nov 2023 to 492× in Jul 2018.

EV/EBIT over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
202433.7×16.7×33.7×
202322.3×16.7×22.7×
2022n/m a value too high to mean anything
2021n/m a value too high to mean anything
2020n/m a value too high to mean anything
2019477×127×488×
2018120×57.4×492×
201732.2×21.5×34.0×
2016155×23.3×403×
201526.2×23.8×41.5×
201441.4×32.8×157×
201392.4×70.3×92.4×

Against its peers

Companies in Medical - Instruments & Supplies nearest Angiodynamics' size, closest first, today.

CompanyEV/EBIT
ANGOAngiodynamicsn/m
TCMDTactile Systems Technology13.3×
MDXGMimedx51.6×
MOVMovado11.8×
EMBCEmbecta6.7×
INFUInfuSystem22.4×
IRMDIradimed37.7×
STAAStaar Surgical57.7×
UTMDUtah Medical Products6.0×
BVSBioventus26.2×
CDRECadre23.2×
Peer median22.8×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Angiodynamics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.